



27 February 2023

## Notice under section 708A(5)(e) of the Corporations Act

Emyria Limited ("Issuer") notifies ASX (as the operator of the prescribed financial market on which the securities identified below are or are to be quoted) under section 708A(5)(e) of the Corporations Act that:

1. the securities identified below were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and with section 674 of the Corporations Act; and
3. as at the date of this notice, there is no excluded information of the type referred to in sub-sections 708A(7) and 708A(8) of the Corporations Act.

| DETAILS OF THE SECURITIES ISSUED |                  |
|----------------------------------|------------------|
| Class of Securities:             | Ordinary Shares  |
| ASX Code of the Securities:      | EMD              |
| Date of the issue of securities: | 23 February 2023 |
| Total number of Shares issued:   | 833,333          |

**Release authorised by The Board of Directors of the Company.**

For further information on Emyria, please contact:

Dr. Michael Winlo  
**Managing Director**  
1300 436 363  
mwinlo@emyria.com

Lexi O'Halloran  
**Investor Relations**  
+ 61 (0) 404 577 076  
lexi@janemorganmanagement.com.au

Andrew Williams  
**Media Relations**  
+61 (0) 412 614 125  
andrew@profilemedia.com.au

**myriad data.**  
**individual care.**

Emyria Limited • ABN 96 625 085 734 • [info@emyria.com](mailto:info@emyria.com) •  
Talk 1300 436 363 • Suite 3, 43 Oxford Close, West Leederville •  
PO Box 1442, West Leederville, Western Australia 6901 • [emyria.com](http://emyria.com)



### **About Emyria ([www.emyria.com](http://www.emyria.com))**

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- Drug Development: Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for registration against multiple indications. Emyria's first dose form, EMD-RX5, is in Phase 3 trials.
- New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- Proprietary Real-World Data (RWD): Emyria gathers robust and ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.